Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.

Su K, Lv C, Ji Z, Wang Y, Wang H, Bai Y, Liu Y

American journal of therapeutics1 Nov 2018Cited by 2 (Europe PMC)

PMID26844723DOI10.1097/mjt.0000000000000431PepBankPUB-26844723

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In poorly controlled type 2 diabetes, normal-dose exenatide/metformin/biphasic insulin aspart reduced HbA1c more than the low-dose regimen.
In plain wordsIn type 2 diabetes, the normal-dose triple regimen reduced HbA1c more than the low-dose regimen.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c normal-dose regimen
Study
n = 172
Comparator
Low-dose triple regimen
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−2.5%
normal-dose regimen
HbA1c change
−0.8%
low-dose regimen
Source sentences
Summary
The normal-dose treatment was more effective at lowering hemoglobin A1c levels than the low-dose therapy (HbA1c changes of -2.5 ± 0.19% and -0.8 ± 0.07%, respectively) after 48 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred patients with poorly controlled T2DM were randomly divided into the low-dose (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily) and normal-dose (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily) groups for 48 weeks of treatment.
Summary · context
Of note, 82 and 90 individuals from the low-dose and normal-dose groups, respectively, completed the study.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2684472301
02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In type 2 diabetes, exenatide/metformin/biphasic insulin aspart increased insulin sensitivity.
In plain wordsIn type 2 diabetes, the triple regimen increased insulin sensitivity.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInsulin sensitivity
Study
n = 172
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The triple combination therapy increased the levels of insulin sensitivity and adiponectin and reduced the levels of C-reactive protein, resistin, and tumor necrosis factor-α.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred patients with poorly controlled T2DM were randomly divided into the low-dose (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily) and normal-dose (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily) groups for 48 weeks of treatment.
Summary · context
Of note, 82 and 90 individuals from the low-dose and normal-dose groups, respectively, completed the study.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2684472305
03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism
In type 2 diabetes, exenatide/metformin/biphasic insulin aspart increased adiponectin.
In plain wordsIn type 2 diabetes, the triple regimen increased adiponectin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAdiponectin
Study
n = 172
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The triple combination therapy increased the levels of insulin sensitivity and adiponectin and reduced the levels of C-reactive protein, resistin, and tumor necrosis factor-α.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred patients with poorly controlled T2DM were randomly divided into the low-dose (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily) and normal-dose (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily) groups for 48 weeks of treatment.
Summary · context
Of note, 82 and 90 individuals from the low-dose and normal-dose groups, respectively, completed the study.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2684472306
04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism
In type 2 diabetes, exenatide/metformin/biphasic insulin aspart reduced C-reactive protein.
In plain wordsIn type 2 diabetes, the triple regimen reduced C-reactive protein.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseC-reactive protein
Study
n = 172
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
The triple combination therapy increased the levels of insulin sensitivity and adiponectin and reduced the levels of C-reactive protein, resistin, and tumor necrosis factor-α.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred patients with poorly controlled T2DM were randomly divided into the low-dose (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily) and normal-dose (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily) groups for 48 weeks of treatment.
Summary · context
Of note, 82 and 90 individuals from the low-dose and normal-dose groups, respectively, completed the study.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2684472307
05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism
In type 2 diabetes, exenatide/metformin/biphasic insulin aspart reduced resistin.
In plain wordsIn type 2 diabetes, the triple regimen reduced resistin.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseResistin
Study
n = 172
Outcome group
Inflammation markers · Metabolic and weight
Source sentences
Summary
The triple combination therapy increased the levels of insulin sensitivity and adiponectin and reduced the levels of C-reactive protein, resistin, and tumor necrosis factor-α.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred patients with poorly controlled T2DM were randomly divided into the low-dose (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily) and normal-dose (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily) groups for 48 weeks of treatment.
Summary · context
Of note, 82 and 90 individuals from the low-dose and normal-dose groups, respectively, completed the study.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2684472308
06HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism
In type 2 diabetes, exenatide/metformin/biphasic insulin aspart reduced tumor necrosis factor-α.
In plain wordsIn type 2 diabetes, the triple regimen reduced tumor necrosis factor-α.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTumor necrosis factor-α
Study
n = 172
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
The triple combination therapy increased the levels of insulin sensitivity and adiponectin and reduced the levels of C-reactive protein, resistin, and tumor necrosis factor-α.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred patients with poorly controlled T2DM were randomly divided into the low-dose (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily) and normal-dose (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily) groups for 48 weeks of treatment.
Summary · context
Of note, 82 and 90 individuals from the low-dose and normal-dose groups, respectively, completed the study.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2684472309
07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome
In type 2 diabetes, adverse effects did not significantly differ between normal-dose and low-dose triple regimens.
In plain wordsIn type 2 diabetes, adverse effects did not significantly differ between normal-dose and low-dose triple regimens.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAdverse effects
Study
n = 172
Comparator
Low-dose triple regimen
Outcome group
Adverse events · Whole body
Source sentences
Summary
No significant difference in the adverse effects was found between the low-dose and normal-dose groups (P > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred patients with poorly controlled T2DM were randomly divided into the low-dose (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily) and normal-dose (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily) groups for 48 weeks of treatment.
Summary · context
Of note, 82 and 90 individuals from the low-dose and normal-dose groups, respectively, completed the study.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2684472310
08HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In type 2 diabetes, the maximum weight decrease with normal-dose triple therapy was 4.0 kg.
In plain wordsIn type 2 diabetes, the maximum weight decrease with normal-dose triple therapy was 4.0 kg.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMaximum weight decrease normal-dose regimen
Study
n = 90
Outcome group
Body weight · Metabolic and weight
Measurements
Maximum weight decrease
4 kg
normal-dose regimen
Source sentences
Summary
The maximum weight decrease was 0.9 kg in the low-dose group and 4.0 kg in the normal-dose group.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred patients with poorly controlled T2DM were randomly divided into the low-dose (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily) and normal-dose (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily) groups for 48 weeks of treatment.
Summary · context
Of note, 82 and 90 individuals from the low-dose and normal-dose groups, respectively, completed the study.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2684472304
09HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In poorly controlled type 2 diabetes, low-dose triple therapy reduced HbA1c from baseline.
In plain wordsIn type 2 diabetes, low-dose triple therapy reduced HbA1c from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c low-dose regimen
Study
n = 82
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−0.8%
low-dose regimen
Source sentences
Summary
The normal-dose treatment was more effective at lowering hemoglobin A1c levels than the low-dose therapy (HbA1c changes of -2.5 ± 0.19% and -0.8 ± 0.07%, respectively) after 48 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred patients with poorly controlled T2DM were randomly divided into the low-dose (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily) and normal-dose (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily) groups for 48 weeks of treatment.
Summary · context
Of note, 82 and 90 individuals from the low-dose and normal-dose groups, respectively, completed the study.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2684472302
10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In type 2 diabetes, the maximum weight decrease with low-dose triple therapy was 0.9 kg.
In plain wordsIn type 2 diabetes, the maximum weight decrease with low-dose triple therapy was 0.9 kg.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMaximum weight decrease low-dose regimen
Study
n = 82
Outcome group
Body weight · Metabolic and weight
Measurements
Maximum weight decrease
0.9 kg
low-dose regimen
Source sentences
Summary
The maximum weight decrease was 0.9 kg in the low-dose group and 4.0 kg in the normal-dose group.
2 context sentences(design, population, supporting numbers)
Summary · context
Two hundred patients with poorly controlled T2DM were randomly divided into the low-dose (0.5 μg exenatide, 0.05 U·kg·d BIA30, and 0.01 g MET twice daily) and normal-dose (2 μg exenatide, 0.2 U·kg·d BIA30, and 0.05 g MET twice daily) groups for 48 weeks of treatment.
Summary · context
Of note, 82 and 90 individuals from the low-dose and normal-dose groups, respectively, completed the study.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2684472303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.